Sacubitril-Valsartan Initiation in Chronic Heart Failure Patients Impacts Sleep Apnea: The ENTRESTO-SAS Study
Authors:
Open Access
- 8 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (4) , 2513-2526
Abstract
Aims Optimizing medical cardiac treatment for sleep apnoea (SA) in patients with chronic heart failure and reduced ejection fraction (HFrEF) is an expert Grade C recommendation based on six studies encompassing a total of 67 patients only. Whether sacubitril–valsartan (SV), a cornerstone of HFrEF medical treatment, impacts SA is unknown and requires evaluation. Methods and results The ENTRESTO-SAS trial is a six-centre, prospective, open-label real-life cohort study (NCT02916160). Ambulatory patients eligible for SV (i.e. HFrEF adults who remain symptomatic despite optimal treatment) were evaluated before and after 3 months of SV (including nocturnal ventilatory polygraphy); 118 patients were final analysed [median age was 66 (IQ25–75: 56–73) years, 81.4% male, 36.5% New York Heart Association III–IV, N-terminal pro-B-type natriuretic peptide level of 1564 (701–3376) ng/L, left ventricular ejection fraction of 30 (25–34)%, 60.7% ischaemic HFrEF, 97.5% initially treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, 83.9% with beta-blockers, 64.4% with mineralocorticoid receptor antagonists, and 74.6% with diuretics]. Three groups were defined according to initial central/obstructive apnoea–hypopnoea indices (AHIs): G1 (n = 49, AHIcentral ≥ 5/h and AHIobstructive < 15/h); G2 (n = 27, AHIobstructive ≥ 15/h); and G3 (n = 42, AHIcentral < 5/h and AHIobstructive < 15/h). At 3 months, the AHI (main predefined outcome) decreased significantly by −7.10/h (IQ25–75: −16.10 to 0.40; P < 0.001) in G1 + G2 without positive airway pressure treatment (45 patients, median initial AHI of 24.20 (IQ25–75: 16.40–43.50)/h). Of these, 24.4% presented an AHI decrease ≥50% and 37.78% had a final AHI < 15/h (tendency for improvement from an initial value of 20%: P = 0.0574). For G1 patients (n = 37), AHI significantly decreased from a median of 22.90 (16.00–43.50)/h to 19.20 (12.70–31.10)/h (P = 0.002). For G2 patients (n = 8), AHI decreased from a median of 30.10 (26.40–47.60)/h to 22.75 (14.60–36.90)/h (statistically non-significant, P = 0.059). Conclusions In this real-life population, SV treatment for 3 months in SA patients is associated with a significant decrease in AHI. These results support the current guidelines that recommend first an optimization of the HFrEF treatment in patients with HFrEF and central SA. A potential positive airway pressure sparing effect merits further investigation.Keywords
Funding Information
- Novartis
- Novartis
This publication has 46 references indexed in Scilit:
- Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measuresHeart Failure Reviews, 2013
- Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated EventsJournal of Clinical Sleep Medicine, 2012
- The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-AnalysesSLEEP, 2012
- Sleep Apnea Testing and Outcomes in a Large Cohort of Medicare Beneficiaries with Newly Diagnosed Heart FailureAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Population Impact of Heart Failure and the Most Common Forms of CancerCirculation: Cardiovascular Quality and Outcomes, 2010
- Prospective Study of Obstructive Sleep Apnea and Incident Coronary Heart Disease and Heart FailureCirculation, 2010
- Prognosis of Patients With Heart Failure and Obstructive Sleep Apnea Treated With Continuous Positive Airway PressureChest, 2008
- Diuretics in Obstructive Sleep Apnea With Diastolic Heart FailureChest, 2007
- Suppression of Central Sleep Apnea by Continuous Positive Airway Pressure and Transplant-Free Survival in Heart FailureCirculation, 2007
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990